June 1, 2016 — Alzeca Biosciences announced successful preliminary results for ADx, its novel, proprietary diagnostic imaging technology. The technology is designed to enable diagnosis of Alzheimer’s Disease for the first time on conventional magnetic resonance imaging (MRI), providing results a decade or more before the onset of symptoms of cognitive decline.

The American Society of Echocardiography (ASE) will host its 27th Annual Scientific Sessions, June 10-14, 2016, at the Washington State Convention Center in Seattle.


Predictions are usually based less on what will come than what has been. They are projections of the recent past. That realization makes me a little bit nervous when it comes to enterprise imaging. 



In recent years, intraoperative radiation therapy (IORT) has been growing in acceptance in the U.S. as an alternative to traditional external beam radiation therapy (EBRT) for patients with early-stage breast cancer. For patients meeting appropriate selection criteria, the benefits are clear — shorter treatment times, added convenience, lower costs and fewer complications.[1, 2] 



Presentism” is the idea and adherence to view current situations as inevitable and as status quo. Consider your medical imaging operations and the business requirements for further optimization and integration — they will be successful if you can chart where you are currently and navigate to the desired objective, which may or may not be enterprise imaging.



As radiation therapy continues to evolve, new techniques and technologies are largely focused on maximizing the dose to the tumor site while protecting surrounding tissue as much as possible. Image guidance is a critical component of treatment planning for tumor delineation and gauging treatment response, and cone beam computed tomography (CBCT) has traditionally been the modality of choice. 



ITN Associate Editor Jeff Zagoudis spoke with Richard Morin, Ph.D., Brooks-Hollern Professor of Medical Physics, Mayo Clinic, Jacksonville, Fla., and co-chair of the Image Wisely committee, about the latest efforts in computed tomography (CT) dose reduction: 



The trend toward consolidation in the healthcare industry continues to climb, with U.S. hospital mergers and acquisitions at their highest since 1999.


A new Phase III clinical trial will look to evaluate if magnetic resonance imaging (MRI) can replace the current standard of care to diagnose prostate cancer.

Researchers have new evidence that readily obtainable measures of the amount of glucose (sugar) consumed by the brain can directly predict a person's current level of awareness, or the likelihood that they will recover awareness within a year of a severe brain injury.

Subscribe Now